ESR1 and breast carcinoma: Further, a study by the Shapiro laboratory showed that progestin stimulates the proliferation of breast cancer cells harboring mutant ERα that reduced sensitivity to antiestrogen treatments (24), providing further support to an antiprogestin treatment regimen.